{
  "ticker": "IBX",
  "pdf_display_url": "https://www.asx.com.au/asx/v2/statistics/displayAnnouncement.do?display=pdf&idsId=02976454",
  "id": "02976454",
  "pages": 5,
  "price_sensitive": false,
  "date": "20250804",
  "time": "0935",
  "pdf_url": "https://announcements.asx.com.au/asxpdf/20250804/pdf/06mhk5ldxqk91k.pdf",
  "summary": "- **Capital Raising Type**: Placement  \n- **Total Securities Issued**: 45,000,000 ordinary fully paid shares (IBX)  \n- **Issue Price**: AUD 0.015 per share  \n- **Proposed Issue Date**: 6 August 2025  \n- **Use of Proceeds**: Advance MagSense\u00ae technology (HER2 Breast Cancer) and Phase 1 trials for prostate/ovarian cancer  \n- **Capacity Breakdown**:  \n  - 25,300,000 shares (15% placement capacity)  \n  - 19,700,000 shares (10% placement capacity under 7.1A)  \n- **Broker**: CPS Capital Group Pty Ltd (fees: 2% management, 4% capital raising, payable in shares at placement price)  \n- **No underwriting or shareholder approval required**.  \n\n*No material information omitted; all key terms captured.*",
  "usage": {
    "prompt_tokens": 1932,
    "completion_tokens": 187,
    "total_tokens": 2119,
    "prompt_tokens_details": null
  },
  "model": "deepseek/deepseek-chat-v3-0324:free",
  "processed_at": "2025-08-03T23:48:41.414960"
}